Daunorubicin
Modify Date: 2024-01-03 00:56:59
Daunorubicin structure
|
Common Name | Daunorubicin | ||
|---|---|---|---|---|
| CAS Number | 20830-81-3 | Molecular Weight | 527.520 | |
| Density | 1.6±0.1 g/cm3 | Boiling Point | 770.0±60.0 °C at 760 mmHg | |
| Molecular Formula | C27H29NO10 | Melting Point | 155ºC | |
| MSDS | N/A | Flash Point | 419.5±32.9 °C | |
Use of DaunorubicinDaunorubicin is a topoisomerase II inhibitor. |
| Name | daunorubicin |
|---|---|
| Synonym | More Synonyms |
| Description | Daunorubicin is a topoisomerase II inhibitor. |
|---|---|
| Related Catalog | |
| Target |
Topoisomerase II |
| In Vitro | The mean IC50 value is 0.04 μM for Daunorubicin (Dnr) in Molt-4 cells. Daunorubicin belongs to the anthracyclines, a group of cytotoxic chemotherapeutics. The cytotoxic effects of anthracyclines are caused by DNA intercalation and the ability to interfere with DNA transcription and replication by inhibiting Topoisomerase II as well as by producing reactive oxygen species[2] Daunorubicin inhibits of both DNA and RNA syntheses in HeLa cells over a concentration range of 0.2 through 2 μM. The IC50 value is 0.4 μM for Daunorubicin (Dnr) in human pancreatic cell line L3.6[3]. |
| In Vivo | Urinary protein excretion, serum creatinine, and blood urea nitrogen (BUN) level are significantly increased in group Daunorubicin (3 mg/kg, i.v.) compared with those in group Control. Administration of Daunorubicin (DNR) causes a significant increase in malondialdehyde (MDA) level in renal tissue compared with that in the control group[4]. |
| Cell Assay | The chemosensitivity to Daunorubicin is assessed using the MTT assay. In brief, the 96 well plates are set up with cells at the initial density of 2×105 cells/mL and are incubated at 37°C for 72 h in an atmosphere of 5% CO2 in the absence and presence of nine different concentrations of Daunorubicin (Dnr) or Dox ranging from 1.90 to 0.007 μM in triplicate. After incubation, 10 μL of MTT solution (5 mg/mL tetrazolium salt) is added to each well and the plates are incubated for a further 4 h at 37°C. The formazan salt crystals are dissolved by adding 100 μL 10% SDS in 10 mM HCl solution and incubating over night at 37°C. The absorbance is measured at 540 nm with a reference at 650 nm by a 96-well enzyme-linked immunosorbent assay (ELISA) plate reader. Chemosensitivity is expressed as the IC50, which is the concentration of drug causing 50% cell survival compare to control cells grown without drug. Calculations are carried out using Microsoft Excel[2]. |
| Animal Admin | Rat[4] Eight-week-old male Sprague-Dawley rats are used. The animals are quarantined and acclimatized for the additional 2 weeks prior to the initiation of the experiments. On day 0, each animal receives a single intravenous injection of Daunorubicin at a dose of 3 mg/kg (i.v.). Daunorubicin is administered in three equal injections at 48 h intervals for a period of one week to achieve an accumulative dose of 9 mg/kg, which is well documented to produce cardiotoxicity and nephrotoxicity. Age-matched rats are injected with corresponding volumes of 0.9% NaCl and used as a control (group Control;n=5). Twenty-two DNR-treated rats are randomly divided into two groups and received oral administration of Telmisartan (10 mg/kg/day; group Daunorubicin+Telmisartan; n=10) or vehicle (group Daunorubicin; n=12). The dose of Telmisartan is chosen on the basis of a previous report. Administration of Telmisartan is started on the same day as Daunorubicin administration and continued for 5 additional weeks after cessation of Daunorubicin administration (6 weeks total period). This duration of study is chosen on the basis of previous reports. On day 41, rats are placed individually in metabolic cages for 24-h urine collections for the measurement of protein concentrations and body weight (BW) is measured. After the end of the study period (6 weeks), rats are sacrificed and kidney tissue is harvested for semi-quantitative immunoblotting and immunohistochemical studies. |
| References |
| Density | 1.6±0.1 g/cm3 |
|---|---|
| Boiling Point | 770.0±60.0 °C at 760 mmHg |
| Melting Point | 155ºC |
| Molecular Formula | C27H29NO10 |
| Molecular Weight | 527.520 |
| Flash Point | 419.5±32.9 °C |
| Exact Mass | 527.179138 |
| PSA | 185.84000 |
| LogP | 2.92 |
| Vapour Pressure | 0.0±2.8 mmHg at 25°C |
| Index of Refraction | 1.692 |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
MUTATION DATA
|
| Risk Phrases | R3249 |
|---|---|
| RIDADR | UN 3249 |
| Packaging Group | III |
| Hazard Class | 6.1(b) |
|
~%
Daunorubicin CAS#:20830-81-3 |
| Literature: EP2660255 A1, ; Page/Page column ; |
|
~%
Daunorubicin CAS#:20830-81-3
Detail
|
| Literature: Journal of the American Chemical Society, , vol. 113, # 1 p. 308 - 315 |
|
~%
Daunorubicin CAS#:20830-81-3 |
| Literature: Journal of Medicinal Chemistry, , vol. 23, # 11 p. 1166 - 1170 |
|
~%
Daunorubicin CAS#:20830-81-3 |
| Literature: Bioorganic and Medicinal Chemistry, , vol. 7, # 8 p. 1597 - 1610 |
|
~%
Daunorubicin CAS#:20830-81-3 |
| Literature: Bioorganic and Medicinal Chemistry, , vol. 7, # 8 p. 1597 - 1610 |
|
~%
Daunorubicin CAS#:20830-81-3 |
| Literature: Tetrahedron Letters, , vol. 41, # 25 p. 4871 - 4874 |
![N-[4-(daunorubicin-N-carbonyloxymethyl)phenyl] O-β-D-glucopyranosyl carbamate structure](https://image.chemsrc.com/caspic/269/186653-73-6.png)
| Precursor 3 | |
|---|---|
| DownStream 8 | |
CAS#:52744-22-6
CAS#:28008-55-1
CAS#:32384-98-8![N-[6-[(3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-2,4-dihydro-1H-tetracen-1-yl)oxy]-3-hydroxy-2-methyloxan-4-yl]acetamide structure](https://image.chemsrc.com/caspic/437/32385-10-7.png)
CAS#:32385-10-7
CAS#:131079-86-2
CAS#:53153-46-1
CAS#:62133-95-3| (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside |
| DAUNOMYCIN |
| daunamycin |
| 5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S-cis)- |
| (1S,3S)-3-Acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydro-1-tetracenyl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside |
| (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro--6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione |
| daunoxome |
| (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione |
| fi6339 |
| 5,12-Naphthacenedione, 8-acetyl-10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S,10S)- |
| cerubidin |
| rubomycinc |
| 5,12-Naphthacenedione, 8-acetyl-10-((3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-, (8S-cis)- |
| Daunorubicin |
| (8S,10S)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione |
| (8S,10S)-8-Acetyl-10-{[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-6,8,11-trihydroxy-1-methoxy-7,8,9,10-tetrahydrotetracen-5,12-dion |
| (8S,10S)-8-acétyl-10-{[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-méthyltétrahydro-2H-pyran-2-yl]oxy}-6,8,11-trihydroxy-1-méthoxy-7,8,9,10-tétrahydrotétracène-5,12-dione |
| EINECS 245-723-4 |
| (8S,10S)-8-acetyl-10-{[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-6,8,11-trihydroxy-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione |
| Cerubidine(R) |
| (1S,3S)-3-Acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside |
| (8S,10S)-8-Acetyl-10-{[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-6,8,11-trihydroxy-1-methoxy-7,8,9,10-tetrahydro-5,12-tetracenedione |
| daunorubicinum [INN_la] |
| RUBIDOMYCIN |